Cancer Network

09/25/2025

The confirmed ORR with the regimen was 50% among patients with ATM-negative cancers, with a median duration of response of 5.7 months.

https://hubs.ly/Q03KV7B-0

09/25/2025

The FDA has accepted and granted priority review to T-DXd plus pertuzumab in a new indication.

Read here for more information: https://hubs.ly/Q03KV1TD0

Results from the phase 3 DESTINY-Breast09 trial will support the FDA’s decision on whether to approve T-DXd plus pertuzumab in frontline metastatic breast cancer.

09/24/2025

Updated findings from the AURIGA trial support the addition of subcutaneous daratumumab to lenalidomide maintenance in MRD-positive NDMM after transplant.

https://hubs.li/Q03KrKyJ0

Updated findings from AURIGA support the value of adding subcutaneous daratumumab to lenalidomide maintenance in MRD-positive NDMM after transplant.

09/24/2025

New Issue Alert!

The September issue of ONCOLOGY® spotlights the critical role of molecular diagnostics in unraveling a rare glioblastoma case with atypical features. Discover how advanced molecular profiling reveals hidden disease drivers and informs more precise diagnosis and treatment strategies.

🧬 Uncover the full story in ONCOLOGY®: https://hubs.li/Q03KPySr0

09/24/2025

According to Michael Wang, MD, results from this phase 2 trial were tremendous and showed that mosunetuzumab plus polatuzumab vedotin is viable in MCL.

https://hubs.li/Q03KrKvD0

| MD Anderson Cancer Center

09/24/2025

Conferences mean career opportunities.
Learn how oncology fellows can set goals, prepare, and network effectively in our new video series.
Watch now: https://hubs.li/Q03J6sKF0

09/24/2025

The EMA's CHMP has recommended approval for pembrolizumab as subcutaneous injection in all previous solid tumor indications, and as IV in locally advanced HNSCC.

https://hubs.li/Q03KrHPD0

The agency has recommended approval for subcutaneous pembrolizumab in all previous solid tumor indications, and for pembrolizumab in recurrent HNSCC.

09/24/2025

Check out this soundbite from , as Benjamin Garmezy, MD, and Kerry R. Schaffer, MD, discuss radioligand therapies for prostate cancer.

https://youtube.com/shorts/hXHWTE4Fs68?si=VnCLww-ZKjwBovPl

In an upcoming Oncology Decoded Podcast, Benjamin Garmezy, MD, associate director of genitourinary research and executive cochair of the Genitourinary Cancer...

09/23/2025

Patients with PDAC and non-GOF mutations had less favorable OS and DFS outcomes in various instances, when compared with those who had wild-type or GOF mutations.

https://hubs.li/Q03KrnMM0

Patients with PDAC and non-GOF mutations had less favorable OS and DFS outcomes in various instances compared with those who had wild-type or GOF mutations.

09/23/2025

Isa-VRd met the primary end point of the phase 2 ISASOCUT trial, achieving a VGPR or better rate of 87.8% in patients with transplant-ineligible newly diagnosed multiple myeloma.

https://hubs.li/Q03Kr36K0

The VGPR or better rate was 87.8% in patients treated with Isa-VRd who had transplant-ineligible newly diagnosed multiple myeloma.

09/23/2025

Take a peek at this soundbite from , and listen to Benjamin Garmezy, MD, and Mehmet Asim Bilen, MD, discuss multidisciplinary GU cancer care.

https://youtube.com/shorts/FUy4r7WTVh4?si=6LN9XiUd5ZJILa7p

In an upcoming Oncology Decoded Podcast, Benjamin Garmezy, MD, associate director of genitourinary research and executive cochair of the Genitourinary Cancer...

09/23/2025

The median OS and PFS were 14.9 months and 7.8 months, respectively, with mitazalimab plus mFOLFIRINOX in previously untreated patients with PDAC.

https://hubs.li/Q03KqNht0